NLY02 / D&D Pharmatech, 1ST Bio - LARVOL DELTA

1ST Bio and D&D Pharmatech win US patent for disease-modifying Parkinson’s drug (Korea Biomedical Review) - "1ST Biotherapeutics and D&D Pharmatech have secured a U.S. patent for NLY02, an oral small molecule in development for neurodegenerative diseases including Parkinson’s and Alzheimer’s, the companies said Wednesday."

Patent • Alzheimer's Disease • Parkinson's Disease